IRIS
BRESCIA MORRA, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.650
EU - Europa 2.333
AS - Asia 707
AF - Africa 82
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 6.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.565
IT - Italia 1.070
CN - Cina 488
NL - Olanda 306
DE - Germania 222
FI - Finlandia 168
IE - Irlanda 161
UA - Ucraina 150
GB - Regno Unito 94
IN - India 85
CA - Canada 83
CI - Costa d'Avorio 80
SE - Svezia 63
IR - Iran 58
VN - Vietnam 56
FR - Francia 38
ES - Italia 14
BR - Brasile 13
BE - Belgio 8
SG - Singapore 7
RU - Federazione Russa 6
CH - Svizzera 4
GR - Grecia 4
HK - Hong Kong 4
JP - Giappone 4
PL - Polonia 4
MK - Macedonia 3
PT - Portogallo 3
AR - Argentina 2
BG - Bulgaria 2
CO - Colombia 2
EU - Europa 2
HU - Ungheria 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
AP - ???statistics.table.value.countryCode.AP??? 1
AU - Australia 1
AZ - Azerbaigian 1
BZ - Belize 1
CZ - Repubblica Ceca 1
HR - Croazia 1
IM - Isola di Man 1
LT - Lituania 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
QA - Qatar 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 6.793
Salva come PNG Salva come JPEG
Città #
Chandler 761
Amsterdam 298
Ashburn 263
Millbury 249
Naples 222
Princeton 180
Napoli 175
Nanjing 143
Beijing 141
Des Moines 122
Boston 97
Norwalk 85
Wilmington 81
Lawrence 74
Ottawa 68
Jacksonville 64
Dong Ket 56
Milan 49
Nanchang 47
Seattle 37
Krefeld 33
Hebei 30
Rome 30
Tianjin 26
Dublin 25
Pune 25
Jiaxing 23
Augusta 20
Cava De' Tirreni 20
Shenyang 20
San Mateo 18
Washington 18
Dearborn 16
Houston 15
Rottweil 15
Fairfield 13
Los Angeles 13
Kronberg 12
New York 12
Sant'arpino 12
Woodbridge 12
Bari 11
Nola 11
Redwood City 11
Guangzhou 10
Lappeenranta 10
Changsha 9
Ann Arbor 8
Council Bluffs 8
Falls Church 8
Stockholm 8
Toronto 8
Vermezzo 8
Faenza 7
Formia 7
Frankfurt am Main 7
Montalbano Jonico 7
Saint Louis 7
Salerno 7
Bilbao 6
Boardman 6
Caposele 6
Capri 6
Chengdu 6
London 6
San Jose 6
Shenzhen 6
Torre Annunziata 6
Vicenza 6
Ardabil 5
Aversa 5
Caserta 5
Indiana 5
Kunming 5
Leawood 5
Mountain View 5
Qualiano 5
Wuhan 5
Casoria 4
Castellammare Di Stabia 4
Catania 4
Forino 4
Helsinki 4
Hong Kong 4
Marsala 4
Mugnano di Napoli 4
Suffern 4
Trapani 4
Turin 4
Bologna 3
Boscoreale 3
Brusciano 3
Changchun 3
Edinburgh 3
Goiânia 3
Hangzhou 3
Las Vegas 3
Menlo Park 3
Modena 3
Moscow 3
Totale 3.954
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 156
Quality of Life and Cognitive function in pediatric and young adults multiple sclerosis: a cross-sectional study 124
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 71
A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis 65
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 62
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 62
SPG5 and multiple sclerosis: clinical and genetic overlap? 59
Vascular alterations in multiple sclerosis and amyotrophic lateral sclerosis : preliminary analysis of susceptibility factors 59
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 57
L'attenzione alle donne nei servizi psicologici offerti dal Centro Regionale Sclerosi Multipla ''Federico II'' di Napoli: l'esperienza del progetto SIM 56
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 56
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis 56
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 56
In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents 53
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 52
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 51
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 51
The use of medical-grade cannabis in patients non-responders to Nabiximols 50
Quality of life and cognitive functions in early onset multiple sclerosis 50
Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis 50
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 50
Brain atrophy and lesion load in a large population of patients with multiple sclerosis 49
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 49
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration 49
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 49
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 47
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 46
A refined physical and transcriptional map of the SPG9 locus on 10q23.3[#150]q24.2 44
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. 44
Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study 44
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 44
Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis 43
A refined physical and transcriptional map of the SPG9 locus on 10q23.3-q24.2. 43
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 43
Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study 43
Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience 43
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 42
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 42
Uric acid: a potential biomarker of multiple sclerosis and of its disability 41
Can people with multiple sclerosis actually understand what they read in the Internet age? 41
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 40
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 40
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 40
A randomized clinical trial of lithium in multiple system atrophy. 39
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 39
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis 39
Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approach 39
Epileptic seizures in multiple sclerosis: clinical and EEG correlations. 38
A multilayer perceptron neural network-based approach for the identification of responsiveness to interferon therapy in multiple sclerosis patients 38
A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. 38
A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis 38
COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak 38
A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis 38
A longitudinal real-life comparison study of natalizumab and fingolimod 37
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 37
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 37
Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). 36
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 36
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis 36
Mobitz type I and II atrioventricular blocks during fingolimod therapy 36
Imaging of brain perfusion in multiple sclerosis and neurodegenerative disorders: association with endothelial factors. An interim analysis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 20, pp. 297-297). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD. 36
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis 36
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study 36
Retinal vascular density in multiple sclerosis: a one year follow up 36
Multiple sclerosis and headache co-morbidity. A case-control study 35
Antiphospholipid-related chorea. 35
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 35
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice 35
Optical coherence tomography angiography in optic nerve sheath meningioma 34
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 33
Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. 33
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 33
The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. 33
ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism 33
Evaluation of optic nerve subarachnoid space in primary open angle glaucoma using ultrasound examination 33
The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis 33
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 33
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 32
Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study 32
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 32
A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. 32
Internal jugular vein blood flow in multiple sclerosis patients and matched controls. 32
Comparative effects of mesoglycan and ticlopidine treatment on some coagulative parameters in patients with previous ischemic stroke: Results of a randomized controlled trial 32
Anti-JC virus antibodies index and JCV DNA concordance and markers of active viral replication: true exposure to JCV virus in natalizumab treated patients. In MULTIPLE SCLEROSIS JOURNAL (Vol. 19, No. 11, pp. 495-496). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD. 32
Longitudinal Assessment of Dentate Nuclei Relaxometry during Massive Gadobutrol Exposure 32
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 32
Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? 31
The importance of being persistent to multiple sclerosis treatments 31
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery 31
Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. 30
Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. 30
The Framingham cardiovascular risk score in multiple sclerosis 30
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study) 30
Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach 30
Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy? 30
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 30
A multiple n-glucosylated peptide epitope efficiently detecting antibodies in multiple sclerosis 30
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 29
Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. 29
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. 29
Totale 4.241
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.020
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.020
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201934 0 0 0 0 0 0 0 0 0 0 24 10
2019/2020839 280 78 42 26 32 33 32 31 28 98 114 45
2020/2021698 56 39 48 87 82 64 41 9 83 16 100 73
2021/20221.355 17 2 12 16 28 78 22 58 179 117 277 549
2022/20232.217 264 177 55 110 238 256 164 173 326 318 98 38
2023/20241.186 51 240 232 104 78 184 71 163 23 38 2 0
Totale 7.446